BSH 2017 | Promising novel treatments in multiple myeloma
Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses promising novel therapies in the treatment of multiple myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. There are currently many promising novel therapies being developed, for example, cellular therapy. Isatuximab, targeting CD38, and has the advantage of a short infusion time. BCMA and CAR T-cell therapy are other promising treatments that have been shown to be effective in advanced stages, and have the potential to be used at earlier stages as well. Checkpoint inhibition, when combined with immunomodulation has also been shown to improve outcomes. There are also very targeted therapies, such as venetoclax, which targets the 11;14 translocation, HDAC inhibitors, and cytotoxics. Due to the complex nature of multiple myeloma, a combination of these modalities will be the more effective than them individually.
Get great new content delivered to your inboxSign up